170 related articles for article (PubMed ID: 38616252)
21. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.
Ma D; Zhang Y; Xing P; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang H; Du Y; Zhang Z; Liang L; Li J
Thorac Cancer; 2019 May; 10(5):1213-1219. PubMed ID: 30993895
[TBL] [Abstract][Full Text] [Related]
23. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
24. Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
Van Damme E; Kiselinova M; Van Schoote E
Tumori; 2019 Dec; 105(6):NP35-NP37. PubMed ID: 31023173
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
[TBL] [Abstract][Full Text] [Related]
26. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
27. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
28. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
29. Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib.
Di Marino P; Mannetta G; Carella C; Grassadonia A; Tinari N; Natoli C; De Tursi M
Int Med Case Rep J; 2020; 13():89-93. PubMed ID: 32214855
[TBL] [Abstract][Full Text] [Related]
30. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
31. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
32. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
34. Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients: A single-institution retrospective analysis.
Gürsoy P; Çakar B; Nart D; Göker E
Indian J Cancer; 2022; 59(2):251-256. PubMed ID: 35017371
[TBL] [Abstract][Full Text] [Related]
35. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
39. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Deng H; Li B; Li L; Peng J; Lv T; Liu Y; Ding C
Pathol Res Pract; 2019 Dec; 215(12):152695. PubMed ID: 31699471
[TBL] [Abstract][Full Text] [Related]
40. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]